Heron Therapeutics' Non-Opioid, Post-Operative Pain Drug Approved For Use In Additional Orthopedic, Soft Tissue Procedures

The FDA has approved Heron Therapeutics Inc’s (NASDAQ:HRTX) supplemental New Drug Application for Zynrelef (bupivacaine and meloxicam) extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures, including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. Zynrelef was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in ad

Related Keywords

, Nasdaq , Heron Therapeutics Inc , New Drug Application , Vial Access Needle , Craig Collard , Chief Executive Officer , Stock Market Game , Benzinga Pro , Day Trial , Heron Therapeutic Non Opioid , Soft Tissue Procedures ,